These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38720564)

  • 1. Liposomal amphotericin for secondary prophylaxis: A systematic review and meta-analysis.
    Javandoust Gharehbagh F; Roshanzamiri S; Farjami M; Hatami F; Lotfollahi L; Kazeminia N; Hatami F; Shokouhi S; Alavi Darazam I
    J Oncol Pharm Pract; 2024 Jul; 30(5):919-929. PubMed ID: 38720564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.
    Annino L; Chierichini A; Anaclerico B; Finolezzi E; Norata M; Cortese S; Cassetta MI; Fallani S; Novelli A; Girmenia C
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2596-602. PubMed ID: 23529741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occurrence and improvement of renal dysfunction and serum potassium abnormality during administration of liposomal amphotericin B in patients with hematological disorders: A retrospective analysis.
    Yamazaki H; Kondo T; Aoki K; Yamashita K; Takaori-Kondo A
    Diagn Microbiol Infect Dis; 2018 Feb; 90(2):123-131. PubMed ID: 29203252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Hypokalemia as a Side Effect of Liposomal Amphotericin in Pediatric Patients.
    Kobayashi R; Keino D; Hori D; Sano H; Suzuki D; Kishimoto K; Kobayashi K
    Pediatr Infect Dis J; 2018 May; 37(5):447-450. PubMed ID: 28945677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Low-Dose Liposomal Amphotericin B in Adult Patients Undergoing Unrelated Cord Blood Transplantation.
    Yasu T; Konuma T; Oiwa-Monna M; Kato S; Tanoue S; Isobe M; Mizusawa M; Kuroda S; Takahashi S; Tojo A
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the safety and cost-effectiveness of nebulized liposomal amphotericin B and amphotericin B deoxycholate for antifungal prophylaxis after lung transplantation.
    Umemura K; Katada Y; Nakagawa S; Hira D; Yutaka Y; Tanaka S; Ohsumi A; Nakajima D; Date H; Nagao M; Terada T
    J Infect Chemother; 2024 Aug; 30(8):741-745. PubMed ID: 38354908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Effectiveness of High-dose Liposomal Amphotericin B: A Systematic Review and Meta-analysis.
    Fu X; Zhang C; Lin X; Zheng X; Liu Q; Jin Y
    Altern Ther Health Med; 2024 Aug; 30(8):127-135. PubMed ID: 37971463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical efficacy and safety of liposomal amphotericin B in the salvage treatment of invasive fungal disease in patients with hematological diseases].
    Wu YB; Jiang SS; Wu YX; Liu B; Jing YT; Bao HY; Ma X; Wu DP; Hu XH
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jul; 45(7):666-671. PubMed ID: 39231771
    [No Abstract]   [Full Text] [Related]  

  • 9. Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.
    Luu Tran H; Mahmoudjafari Z; Rockey M; Henry D; Grauer D; Aljitawi O; Abhyankar S; Ganguly S; Lin T; McGuirk J
    J Oncol Pharm Pract; 2016 Apr; 22(2):228-34. PubMed ID: 25471252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations.
    Cannon JP; Garey KW; Danziger LH
    Pharmacotherapy; 2001 Sep; 21(9):1107-14. PubMed ID: 11560200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the safety and efficacy of liposomal amphotericin B (L-AMB) in children.
    Sunakawa K; Tsukimoto I; Tsunematsu Y; Honda M; Iwai N; Maniwa T; Haigo H; Suzuki K; Mori T
    J Infect Chemother; 2012 Aug; 18(4):456-65. PubMed ID: 22286407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evaluation of frequency of nephrotoxicity caused by liposomal amphotericin B.
    Kato H; Hagihara M; Yamagishi Y; Shibata Y; Kato Y; Furui T; Watanabe H; Asai N; Koizumi Y; Mikamo H
    J Infect Chemother; 2018 Sep; 24(9):725-728. PubMed ID: 29773439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
    Chamilos G; Luna M; Lewis RE; Chemaly R; Raad II; Kontoyiannis DP
    Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of aerosolized deoxycholate amphotericin B to systemic prophylaxis to prevent airways invasive fungal infections in allogeneic hematopoietic SCT: a single-center retrospective study.
    Morello E; Pagani L; Coser P; Cavattoni I; Cortelazzo S; Casini M; Billio A; Rossi G
    Bone Marrow Transplant; 2011 Jan; 46(1):132-6. PubMed ID: 20383205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive intravenous amphotericin B for prophylaxis of systemic fungal infections. Results of a prospective controlled pilot study in acute leukemia patients.
    Karthaus M; Doellmann T; Klimasch T; Elser C; Rosenthal C; Ganser A; Heil G
    Chemotherapy; 2000; 46(4):293-302. PubMed ID: 10859435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
    Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
    Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COMPARATIVE EFFECTIVENESS AND SAFETY BETWEEN AMPHOTERICIN B LIPID-FORMULATIONS: A SYSTEMATIC REVIEW.
    Grazziotin LR; Moreira LB; Ferreira MAP
    Int J Technol Assess Health Care; 2018 Jan; 34(3):343-351. PubMed ID: 29897025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
    Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
    Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.
    Tiphine M; Letscher-Bru V; Herbrecht R
    Transpl Infect Dis; 1999 Dec; 1(4):273-83. PubMed ID: 11428998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-weekly liposomal amphotericin B as Candida prophylaxis in very low birth weight premature infants: a prospective, randomized, open-label, placebo-controlled pilot study.
    Arrieta AC; Shea K; Dhar V; Cleary JP; Kukreja S; Morris M; Vargas-Shiraishi OM; Ashouri N; Singh J
    Clin Ther; 2010 Feb; 32(2):265-71. PubMed ID: 20206784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.